Company Profile
Abeona Therapeutics Stock Price, News & Analysis
- Ticker:
- ABEO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.90 USD (+1.47%)
Close
Last updated: August 6, 2026
324M USD
Market cap
Why the stock is moving
The latest company update was “Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026”. ABEO changed 1.47% and closed at $6.90 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Cell and Gene Therapy Company
Abeona Therapeutics develops and commercializes genetic medicines for serious diseases.
ZEVASKYN
ZEVASKYN is an autologous, gene-corrected epidermal sheet therapy for wounds in recessive dystrophic epidermolysis bullosa and provides Abeona with a commercial cell-therapy platform.
ABO-701
ABO-701 is an engineered T-cell program targeting PSMA in solid tumors and uses synthetic immune-receptor technology intended to improve selectivity and activity.
Future catalysts
Abeona expects to submit an IND for ABO-701 and begin first-in-human development in the second half of 2027.
Recent news
- 01
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
Source: Abeona Therapeutics
- 02
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
Source: Abeona Therapeutics
- 03
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Abeona Therapeutics
- 04
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
Source: Abeona Therapeutics
- 05
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Source: Abeona Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Abeona Therapeutics (ABEO)?
Abeona Therapeutics (ABEO) most recently closed at 6.90 USD, a +1.47% move versus the previous session.
What is the market cap of Abeona Therapeutics (ABEO)?
Abeona Therapeutics currently has a market capitalization of 324M USD on BioPharmSignal.
What does Abeona Therapeutics do?
Cell and Gene Therapy Company Abeona Therapeutics develops and commercializes genetic medicines for serious diseases. ZEVASKYN ZEVASKYN is an autologous, gene-corrected epidermal sheet therapy for wounds in recessive dystrophic epidermolysis bullosa and provides Abeona with a commercial cell-therapy platform. ABO-701 ABO-701 is an engineered T-cell program...
On which exchange is ABEO stock listed?
Abeona Therapeutics (ABEO) is associated with NASDAQ, United States, Biopharma.
What is ABO-701?
Abeona expects to submit an IND for ABO-701 and begin first-in-human development in the second half of 2027.
Which conditions is Abeona Therapeutics targeting with ABO-701?
Abeona Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Abeona Therapeutics describe recent progress with ABO-701?
Abeona expects to submit an IND for ABO-701 and begin first-in-human development in the second half of 2027.
What is Cell?
Cell and Gene Therapy Company Abeona Therapeutics develops and commercializes genetic medicines for serious diseases.